यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals už felidae, - katės - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals už felidae, - katės - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinantinis turkija herpesvirus, kamienas vhvt013-69, gyventi - immunologicals už ave, naminės vištos, immunologicals - embryonated eggs; chicken - aktyvios imunizacijos viščiukų:kad nebūtų mirtingumą ir sumažina klinikinių požymių ir pažeidimų, infekcinės ligos bursal. sumažinti mirtingumą, klinikinių požymių ir pažeidimų, dėl marek liga.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamitromicinas - antibakteriniai preparatai sisteminiam naudojimui - cattle; pigs; sheep - cattletreatment ir metaphylaxis galvijų kvėpavimo takų ligų (brd), susijusių su mannheimia haemolytica, pasteurella multocida ir histophilus somni. ligos buvimas bandoje turi būti nustatytas prieš metafilaksinį naudojimą. pigstreatment kiaulių kvėpavimo takų liga (srd), susijusių su actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis ir bordetella bronchiseptica. sheeptreatment infekcinių pododermatitis (nagų puvinio), susijusių su pavojingiausios dichelobacter nodosus ir fusobacterium necrophorum reikalingas sisteminis gydymas.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ekoparasiticidai sisteminiam vartojimui - Šunys - gydymas nuo blusų (ctenocephalides felis) ir c. canis) infestacijos. produktas gali būti naudojamas kaip dalis gydymo kontrolės strategija, alergijos blusų dermatitas (fad). gydymas, erkių (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestacijos. gydymo demodicosis (dėl demodex canis). gydymo sarcoptic niežų (dėl sarcoptes scabiei var. canis).

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunologiniai vaistai - vištiena - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - katės - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinarinis vaistas yra tik nurodyta, kada visi trys grupes tuo pačiu metu.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - vištiena - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloksetinas - diabetinės neuropatijos - psychoanaleptics, - suaugusiųjų diabetinio periferinio neuropatinio skausmo gydymas.